55583
document
Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia : a pilot study . Studies have shown that insulin resistance is associated with cognitive impairment . Peroxisome proliferator-activated receptor-γ ( PPAR-γ ) agonists improve insulin sensitivity . The purpose of this study was to evaluate the effect of rosiglitazone , a PPAR-γ agonist , on cognition in clozapine-treated patients with schizophrenia . In an eight-week double-blind , placebo-controlled pilot trial , clozapine-treated patients with schizophrenia were randomized to receive rosiglitazone ( 4mg/day ) or placebo . A neuropsychological battery including the Digit Span subtest from the Wechsler Adult Intelligence Scale-III ( WAIS-III ) , the verbal fluency test , the Hopkins Verbal Learning Test ( HVLT ) , the Trail-Making Test ( TMT ) and the Wisconsin Card Sorting Test ( WCST ) was administered at baseline and week eight . Nineteen patients completed the study . There were no significant differences on any demographic or general clinical variables between the rosiglitazone group ( n=9 ) and the placebo group ( n=10 ) . When baseline scores were controlled , there were no significant differences in change scores of cognitive performance over eight weeks between the two groups . In this pilot study , rosiglitazone had no cognitive benefit in clozapine-treated patients with schizophrenia . Future studies with longer treatment duration and larger sample size are needed to further explore the potential role of rosiglitazone in improving cognitive function in patients with schizophrenia .
55584
Intervention_Pharmacological
Rosiglitazone
55585
Intervention_Pharmacological
clozapine-treated
55586
Outcome_Mental
cognitive performance
55587
Outcome_Mental
cognitive benefit
55588
Participant_Condition
schizophrenia